<DOC>
	<DOCNO>NCT02660008</DOCNO>
	<brief_summary>The trial single-centre , randomize , double-blind , parallel trial Group 1 cross-over trial Groups 2-4 single dos ZP4207 administer s.c. hypoglycemic Type 1 diabetic patient evaluate pharmacokinetics pharmacodynamics ZP4207 compare market glucagon .</brief_summary>
	<brief_title>Single Doses ZP4207 Adm. sc Hypoglycemic TD1 pt . Describe PK PD ZP4207 Comp . Marketed Glucagon</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity ( trialrelated activity procedure would perform normal management patient ) . 2 . Male female patient T1D least one year , define American Diabetes Association . 3 . Having treat insulin T1D least 1 year . 4 . Stable disease HbA1c &lt; 8.5 % . 5 . Expected stable insulin treatment participation trial 3 month prior screen visit . 6 . Age 18 50 year , inclusive . 7 . Body weight 60 90 kg , inclusive . 8 . Patients good health accord age ( medical history , physical examination , vital sign , ECG , lab assessment ) , judge Investigator . 1 . Previously treat ZP4207 . 2 . Known suspect allergy trial product ( ) relate product . 3 . Previous participation ( randomization ) trial . 4 . Receipt investigational drug within 3 month prior screen . 5 . A history presence cancer , clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , hematological , dermatological , venereal , neurological , psychiatric disease , major disease . 6 . Clinically significant illness within 4 week screen , judge Investigator . 7 . History , positive result screen test Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibodies 8 . Positive result test HIV antibody . 9 . Any clinically significant abnormal hematology , biochemistry urinalysis screening test , judge Investigator . 10 . Clinically significant abnormal ECG screening evaluate Investigator . 11 . Donation blood plasma past month , excess 500 mL within 12 week prior screen . 12 . A significant history alcoholism drug/chemical abuse , positive result urine drug screen , consume 14 unit alcohol per week ( one unit alcohol equal 250 mL beer , 1 glass wine , 20 mL spirit ) . 13 . Habitual smoking , i.e. , daily smoke 7 cigarettes/week within last 3 month prior screen . Patients accept refrain smoke clinical site . 14 . Patients mental incapacity language barrier preclude adequate understanding cooperation , unwilling participate trial , opinion Investigator participate trial . 15 . Surgery trauma significant blood loss within last 2 month prior screen . 16 . Any condition interfere trial participation evaluation could hazardous patient . 17 . Severe hypoglycaemic event within one year prior screening , judge Investigator . 18 . Significant change basal insulin within 3 week screen , judge Investigator . 19 . Clinically relevant diabetic complication ( macrovascular disease symptom sign coronary artery disease peripheral vascular disease , microvascular disease symptom sign neuropathy , gastroparesis , retinopathy , nephropathy , poor blood glucose control polyuria , polydipsia , weight loss ) , judge Investigator . 20 . Females childbearing potential pregnant , breastfeed intend become pregnant use highly effective contraceptive method ( highly effective contraceptive method consider failure rate le 1 % undesired pregnancy per year include surgical sterilisation , hormonal intrauterine device ( coil ) , oral hormonal contraceptive , sexual abstinence surgically sterilise partner ) postmenopausal woman amenorrheic less 1 year serum FSH level &lt; = 40 IU/L use highly effective contraceptive method trial one month completion trial . 21 . Male sexually active surgically sterilize whose partner ( ) use highly effective contraceptive method ( highly effective contraceptive measure include surgical sterilisation , hormonal intrauterine device [ coil ] , oral hormonal contraceptive , combination spermicidecoated condom ) , willing refrain sexual intercourse first dose one month last dosing trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>